Ubrogepant
Indications
Ubrogepant is used for:
Migraine
Adult Dose
Migraine
Indicated for acute treatment of migraine with or without aura
50-100 mg PO for acute migraine
If needed, may take second dose at least 2 hr after initial dose
Maximum dose: 200 mg/24 hr
Safety of treating >8 migraines/30-day period not established
Hepatic impairment
Mild or moderate (Child-Pugh A or B): No dose adjustment required
Severe (Child-Pugh C)
Initial dose: 50 mg
Second dose (if needed): 50 mg
Child Dose
Renal Dose
Renal impairment
Mild or moderate (CrCl ?30 mL/min): No dose adjustment required
Severe (CrCl 15-29 mL/min)
Initial dose: 50 mg
Second dose (if needed): 50 mg
End-stage renal disease (CrCl <15 mL/min)
Avoid
Administration
Contra Indications
Coadministration with strong CYP3A4 inhibitors
Precautions
Pregnancy-Lactation
Pregnancy
Data are not available regarding risk associated with use in pregnant women
Animal studies
Administration in rats during organogenesis resulted in no adverse effects on embryofetal development
Rabbits
Administration produced abortion and increased embryofetal mortality in surviving litters at high dose (250 mg/kg/day)
In a second study, excessive maternal toxicity at the high dose (250 mg/kg/day) resulted in early termination and lack of fetal data for that dose group
Clinical considerations
Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy
Lactation
Data are not available regarding presence in human milk, effect on breastfed infants, or effects on milk production
Interactions
Adverse Effects
Side effects of Ubrogepant :
1-10%
50 mg
Nausea (2%)
Somnolence (2%)
100 mg
Nausea (4%)
Somnolence (3%)
Dry mouth (2%)
<1%
50 mg
Dry mouth
Mechanism of Action
Highly potent, orally administered calcitonin gene-related peptide (CGRP) receptor antagonist; binds to CGRP receptor, which is thought to be causally involved in migraine pathophysiology